Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation targeted therapies for breast cancer. Its lead candidate, palazestrant (OP-1250), is an oral small molecule acting as both a CERAN and SERD for ER+/HER2- metastatic breast cancer, currently in pivotal Phase 3 trials. Its second candidate, OP-3136, is an oral KAT6 inhibitor in Phase 1 trials for breast and other solid tumor cancers.
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-107169 | EDGAR | 112K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-041204 | EDGAR | 107K words |
| 2024-03-11 | 2023-12-31 | 0000950170-24-029281 | EDGAR | 99K words |
| 2023-03-09 | 2022-12-31 | 0001558370-23-003318 | EDGAR | 101K words |
| 2022-02-28 | 2021-12-31 | 0001558370-22-002388 | EDGAR | — |
| 2021-03-17 | 2020-12-31 | 0001558370-21-003141 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001193125-26-342383 | EDGAR | 79K words |
| 2025-11-10 | 2025-09-30 | 0001193125-25-273236 | EDGAR | 76K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106565 | EDGAR | 75K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070374 | EDGAR | 71K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125427 | EDGAR | 70K words |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091836 | EDGAR | 70K words |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055686 | EDGAR | 68K words |
| 2023-11-07 | 2023-09-30 | 0001558370-23-017994 | EDGAR | 67K words |
| 2023-08-08 | 2023-06-30 | 0001558370-23-013936 | EDGAR | 66K words |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008815 | EDGAR | 64K words |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016903 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001558370-22-012930 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001193125-26-347853 | EDGAR | 1K words |
| 2026-08-10 | 0001193125-26-342334 | EDGAR | 3K words |
| 2026-03-16 | 0001193125-26-107154 | EDGAR | 1K words |
| 2026-01-30 | 0001193125-26-031792 | EDGAR | 6K words |
| 2026-01-12 | 0001193125-26-010507 | EDGAR | 8K words |
| 2025-11-19 | 0001193125-25-288343 | EDGAR | 23K words |
| 2025-11-18 | 0001193125-25-286206 | EDGAR | 1K words |
| 2025-11-10 | 0001193125-25-273228 | EDGAR | 2K words |
| 2025-10-20 | 0001193125-25-243765 | EDGAR | 8K words |
| 2025-09-02 | 0001750284-25-000007 | EDGAR | 1K words |
97 total filings indexed. 69 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001750284 |
| Ticker | OLMA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.olema.com |
| Listed | 2020-11-19 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/OLMA (~200 tokens, structured JSON with cryptographic provenance)